About 42 people will take part in the HVTN 309 clinical trial. This clinical trial will take place at multiple sites in the US and South Africa and the clinical trial is divided into 3 parts: Part A, Part B and Part C. About 3 people will participate in Part A of this study. After results from Part A are reviewed, it will be determined whether or not Part B and Part C of the clinical trial will proceed. conditions: HIV studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: PREVENTION masking: NONE count: 42 type: ESTIMATED name: CD4BS CH505M5 Pr-NP1 name: CH505TF chTrimer name: 3M-052-AF (labeled as AP 60-702) name: Aluminum Hydroxide Suspension (Alum) name: ACU-026-001-1 (labeled as empty LNP) measure: Frequency of local reactogenicity signs and symptoms after receipt of any study vaccine measure: Frequency of systemic reactogenicity signs and symptoms after receipt of any study vaccine measure: Number of serious adverse events (SAEs) leading to early participant withdrawal or permanent discontinuation measure: Number of medically attended adverse events (MAAEs) leading to early participant withdrawal or permanent discontinuation measure: Number of adverse events of special interest (AESIs) leading to early participant withdrawal or permanent discontinuation measure: Number of adverse events (AEs) leading to early participant withdrawal or permanent discontinuation measure: Part C only: Frequency of the CD4BS and CH505M5, G458Y, GNT1-specific, N280D KO IgG+ memory B cells, as assessed by flow cytometry measure: Part C only: Response rate of serum Ab neutralization of vaccine-matched tier 2 HIV-1 strains as measured by TZM-bl assay measure: Part C only: Magnitude of serum Ab neutralization of vaccine-matched tier 2 HIV-1 strains as measured by TZM-bl assay measure: Parts B and C: Response rate of serum IgG binding Abs to autologous and heterologous HIV Env stabilized trimers, as assessed by binding antibody multiplex assay (BAMA) measure: Parts B and C: Magnitude of serum IgG binding Abs to autologous and heterologous HIV Env stabilized trimers, as assessed by binding antibody multiplex assay (BAMA) measure: Part B only: Response rate of serum Ab neutralization of vaccine-matched tier 2 HIV-1 strains as measured by the TZM-bl assay measure: Part B only: Magnitude of serum Ab neutralization of vaccine-matched tier 2 HIV-1 strains as measured by the TZM-bl assay measure: Parts B and C: Response rate of differential serum Ab neutralization of precursor detection virus and corresponding epitope KO virus, as measured by TZM-bl assay measure: Parts B and C: Magnitude of differential serum Ab neutralization of precursor detection virus and corresponding epitope KO virus, as measured by TZM-bl assay measure: Parts B and C: Response rate of serum Ab neutralization of heterologous HIV-1 strains, as measured by TZM-bl assay measure: Parts B and C: Magnitude of serum Ab neutralization of heterologous HIV-1 strains, as measured by TZM-bl assay measure: Parts B and C: Response rate of CD4+ and CD8+ T-cell responses, as measured by flow cytometry measure: Parts B and C: Magnitude of CD4+ and CD8+ T-cell responses, as measured by flow cytometry measure: Part B only: Frequency of the CD4BS and CH505M5, G458Y, GNT1-specific, N280D KO IgG+ memory B cells, as assessed by flow cytometry sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Alabama CRS (Site ID: 31788) city: Birmingham state: Alabama zip: 35222 country: United States name: Heather Logan, A.N.P. role: CONTACT phone: 205-873-8686 email: heatherlogan@uabmc.edu lat: 33.52066 lon: -86.80249 facility: The Ponce de Leon Center CRS (Site ID: 5802) city: Atlanta state: Georgia zip: 30308 country: United States name: Ericka Patrick, M.S.N role: CONTACT phone: 404-616-6313 email: erpatri@emory.edu lat: 33.749 lon: -84.38798 facility: Vanderbilt Vaccine (VV) CRS (Site ID: 30352) city: Nashville state: Tennessee zip: 37232 country: United States name: Shonda E. Sumner, B.S.N. role: CONTACT phone: 615-343-6906 email: Shonda.sumner@vumc.org lat: 36.16589 lon: -86.78444 facility: Setshaba Research Centre CRS (Site ID: 31829) city: Soshanguve state: Gauteng zip: 0152 country: South Africa name: Magdeline K. Molapo role: CONTACT phone: 27-12-7992422 email: KMolapo@setshaba.org.za facility: Isipingo CRS (Site ID: 31635) city: Isipingo state: Kwa Zulu Natal zip: 4110 country: South Africa name: Girisha Kistnasami, B.Sc., D.P.M. role: CONTACT phone: 27-31-2423600 email: girisha.kistnasami@mrc.ac.za lat: -29.98639 lon: 30.91853 facility: Klerksdorp CRS (Site ID: 30325) city: Klerksdorp state: North West Province zip: 2571 country: South Africa name: Olebogeng Jonkane role: CONTACT phone: None Listed email: ojonkane@auruminstitute.org lat: -26.85213 lon: 26.66672 hasResults: False